PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9470486

Head-column field-amplified sample stacking in binary system capillary electrophoresis. 2. Optimization with a preinjection plug and application to micellar electrokinetic chromatography.

C X Zhang·W Thormann
View original source ↗Export metadata ↓

Abstract

In capillary electrophoresis, head-column field-amplified sample stacking (FASS) provides the largest sensitivity enhancement of all electrokinetic concentration techniques (Zhang, C.-X.; Thormann, W. Anal. Chem. 1996, 68, 2523). Application of head-column FASS to the analysis of closely related opioids by capillary zone electrophoresis in binary systems with ethylene glycol is described. It is shown that sample condensation is further increased about 2-fold by introduction of a preinjection plug, i.e., introduction of a short solution plug of high conductivity, high pH, and high viscosity at the capillary tip prior to injection. The preinjection plug acts as a temporary trap for solutes. Its effective length is shown to be limited to a few millimeters. The highest sample stacking efficiency in head-column FASS is obtained via optimization of the electric field strength and the effective electrophoretic mobility of the solutes within the sample and the adjacent zones and is thus strongly dependent on the compositions of both the sample matrix and the preinjection plug. Binary sample solutions of low conductivity and low viscosity containing small amounts of a weak acid are demonstrated to be most effective for the stacking of positively charged opioids. The procedure developed for capillary zone electrophoresis of opioids in binary systems with ethylene glycol and UV absorbance detection is documented to provide a 3 orders of magnitude sensitivity enhancement, exhaustive sample injection from an external reservoir of up to 20 microL (i.e., from a volume that is more than 20-fold the volume of the capillary employed), and a lowest detectable concentration of 0.1 ng/mL (S/N = 3). Using internal calibration, typical intraday and interday imprecisions of solute concentrations between 3 and 10 ng/mL and between 0.5 and 1.5 ng/mL are < or = 5% and < or = 15%, respectively. The stacking approach has been successfully applied to the analysis of dihydrocodeine in extracts of 20 microL of human plasma and is shown to permit the precise (imprecision < or = 10%) determination of dihydrocodeine plasma levels of pharmacological interest (3-300 ng/mL or 10-1000 nM). Furthermore, using a modified protocol for micellar electrokinetic chromatography, head-column FASS is shown to provide a 400-fold sensitivity enhancement for a number of opioids. The stacking procedure is based on insertion of a surfactant-free preinjection plug and temporary application of reversed voltage after electroinjection.

Explore related subjects

Analgesics, OpioidCodeineElectrophoresis, CapillaryHumansMicellesPharmaceutical PreparationsClinical TrialJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C X Zhang, W Thormann. 1998-02-01. Head-column field-amplified sample stacking in binary system capillary electrophoresis. 2. Optimization with a preinjection plug and application to micellar electrokinetic chromatography.. https://doi.org/10.1021/ac9707085

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.

RATIONALE: Sex differences in the potency of the antinociceptive effects of kappa opioids have been reported in various acute pain models with evidence suggesting that these sex differences are mediated by activity in the N-methyl-D: -aspartate (NMDA) system. OBJECTIVES: The purpose of the present study was to evaluate sex differences in the antihyperalgesic actions of selected kappa and mixed-action opioids in a persistent pain model and determine if the NMDA system modulates these effects in a sexually dimorphic manner. METHODS: Using gonadally intact male and female F344 rats, hyperalgesia was induced by local administration of capsaicin in the tail, after which the tail was immersed in a mildly noxious thermal stimulus (45 degrees C water), and tail-withdrawal latency measured. Opioids were then administered systemically (s.c.) and locally (in the tail) alone, and in selected combinations with the noncompetitive NMDA antagonist dextromethorphan. RESULTS: When administered systemically and locally, the kappa opioids spiradoline, U69,593 and U50,488, and the mixed-action opioids butorphanol and nalbuphine, produced dose-dependent antihyperalgesic effects. Whereas the kappa opioids were generally more potent in males, sex differences were not observed with the mixed-action opioids. Peripheral receptor activity was confirmed for local administration of kappa opioids by the antagonism observed after local, but not intracerebroventricular (i.c.v.), administration of the kappa antagonist nor-binaltorphamine (nor-BNI). Dextromethorphan was equally potent in attenuating the antihyperalgesia induced by kappa opioids in both males and females. CONCLUSIONS: These findings demonstrate sex differences in kappa opioid activity in a persistent pain model. Although an NMDA antagonist blocked the effects of kappa opioids in this model, these effects were not sexually dimorphic as reported in most acute pain models.

Analgesics, Opioid↗
PubMed2007

Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.

BACKGROUND: The prevalence, efficacy, and risk for addiction for persons receiving opioids for chronic back pain are unclear. PURPOSE: To determine the prevalence of opioid treatment, whether opioid medications are effective, and the prevalence of substance use disorders among patients receiving opioid medications for chronic back pain. DATA SOURCES: English-language studies from MEDLINE (1966-March 2005), EMBASE (1966-March 2005), Cochrane Central Register of Controlled Clinical Trials (to 4th quarter 2004), PsychInfo (1966-March 2005), and retrieved references. STUDY SELECTION: Articles that studied an adult, nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chronic back pain. DATA EXTRACTION: Two investigators independently extracted data and determined study quality. DATA SYNTHESIS: Opioid prescribing varied by treatment setting (range, 3% to 66%). Meta-analysis of the 4 studies assessing the efficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids (g, -0.199 composite standardized mean difference [95% CI, -0.49 to 0.11]; P = 0.136). Meta-analysis of the 5 studies directly comparing the efficacy of different opioids demonstrated a nonsignificant reduction in pain from baseline (g, -0.93 composite standardized mean difference [CI, -1.89 to -0.03]; P = 0.055). The prevalence of lifetime substance use disorders ranged from 36% to 56%, and the estimates of the prevalence of current substance use disorders were as high as 43%. Aberrant medication-taking behaviors ranged from 5% to 24%. LIMITATIONS: Retrieval and publication biases and poor study quality. No trial evaluating the efficacy of opioids was longer than 16 weeks. CONCLUSIONS: Opioids are commonly prescribed for chronic back pain and may be efficacious for short-term pain relief. Long-term efficacy (> or =16 weeks) is unclear. Substance use disorders are common in patients taking opioids for back pain, and aberrant medication-taking behaviors occur in up to 24% of cases.

Analgesics, Opioid↗